Diagrammatic illustration of the mechanism of two monoclonal antibodies utilized for treating eosinophilic asthma, mepolizumab, and benralizumab. Mepolizumab specifically targets interleukin-5 (IL ...

benralizumab depletes eosinophils directly, and our studies show that eosinophil counts were nearly completely depleted by week 4 of treatment," he said. This new mechanism of action addresses ...

Benralizumab, a monoclonal antibody used to treat severe, uncontrolled asthma, depletes eosinophils through a mechanism of action called antibody-dependent cell-mediated cytotoxicity (ADCC), where ...

Treatment with benralizumab was associated with statistically ... “The OSTRO results show that Fasenra’s eosinophil-depleting mechanism of action may benefit patients with this often ...

FASENRA® (benralizumab) injection for subcutaneous ... 8 Results are descriptive only. FASENRA’s mechanism of action leads to near-complete depletion of eosinophils. 8 The mechanism of action ...

--(BUSINESS WIRE)--Positive high-level results from the MANDARA Phase III trial showed AstraZeneca’s FASENRA (benralizumab ... which has a unique mechanism of action and directly targets ...

Moreover, the biologics that are available have different mechanisms of action, which make it challenging ... omalizumab, benralizumab, or mepolizumab for asthma between November 2018 and ...

Benralizumab is an eosinophil-depleting anti–interleukin-5 receptor α monoclonal antibody. The efficacy and safety of benralizumab in patients with eosinophilic esophagitis are unclear.

“The pathophysiology of CSU is complex, and the interplay of various cell types and molecular mechanisms defines the immune response of CSU.” Despite blood eosinophils depletion, benralizumab ...

Benralizumab was administered subcutaneously at a dose of 30 mg every 4 weeks. The primary end point was the change from baseline to week 20 in the urticaria activity score during a 7-day interval ...

Clinical remission was achieved and sustained in nearly one third of patients with severe eosinophilic asthma (SEA) receiving benralizumab for up to 2 years, with better outcomes in biologic-naive ...

Benralizumab, a monoclonal antibody, has been shown to decrease the number of blood and sputum eosinophils. In this trial of 101 patients with COPD whether benralizumab reduces the number of acute ...